고효능 API 시장 : 제품 종류별, 용도별, 합성 종류별 - 세계 기회 분석과 산업 예측(2021-2031년)

The global high potency APIs market was valued at $19,693.65 million in 2021, and is projected to reach $41,373.34 million by 2031, registering a CAGR of 7.7% from 2022 to 2031.

High potency APIs are the substances that elicit a biological response even at very low doses. Cytotoxic substances and sex hormones like oestrogen are the common examples of HPAPIs which are highly selective in nature and show response at low doses. Moreover, the API development sector including the development of the HPAPIs, is the fastest expanding area of the pharmaceutical industry due to the development of the highly potent drugs such as fentanyl, alprazolam, risperidone, bumetanide, bisoprolol that evokes response at low concentrations and are into the market for the treatment of various ailments. In addition, more than 1,000 highly potent small molecules are under development that have their applications in the treatment of diseases like cancer, diabetes, glaucoma, and others.

According to the National Glaucoma Research, more than three million Americans have glaucoma, and 2.7 million of these patients are aged 40 and older and are affected by its most common form, open-angle glaucoma. Also, in 2020, about 80 million people have glaucoma globally, and this number is expected to increase to over 111 million by 2040. This rise in the number of the glaucoma patients, along with the prevalence of other multi-genetic disorders such as cancer, diabetes, and others around the globe, propel the growth of the high potency APIs market.

Furthermore, the key market players in the market are focusing on the emerging economies such as India, China and the Middle East Asia for investment and expansion of their business. The rise in the population in this region, along with prevalence of the excessive raw materials for the manufacturing and funding offered by the government are the factors driving the growth of the market in this region. In addition, NCBI states that the primary angle closure glaucoma (PACG) is higher in Asians than Europeans and Africans, with over 80% of the total cases globally, which highlights the investment opportunities for the key market players in the high potency APIs market during the forecast period.

In addition, there is an increase in the demand for oncology drugs due to the prevalence of the cancer cases around the globe. Also, advancements in HPAPI manufacturing technologies along with the rise in the number of contract manufacturing organization (CMOs) and contract development and manufacturing organization (CDMOs) are the factors driving the growth of the market. On the other hand, the patent expiry and launch of the generic versions of the highly potent APIs are projected to provide lucrative opportunity for the pharmaceutical companies to enhance product portfolio and expand their business.

However, the market is expected to be significantly constrained in the near future due to the high risk of cross-contamination and high development cost associated with the manufacturing process. The market is capital intensive and requires skilled technical human capital. This is projected to be a major barrier for new entrants entering the market.

The high potency APIs market is segmented on the basis of product type, application, type of synthesis and region. By product type, it is divided into innovative high-potency API and generic high-potency API. On the basis of application, the market is segmented into oncology, hormonal imbalance, glaucoma, and others. According to the type of synthesis, the market is segmented into synthetic and biotech. The biotech is further divided into merchant and captive. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in this report include Abbvie Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd. and others.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the high potency apis market analysis from 2021 to 2031 to identify the prevailing high potency apis market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the high potency apis market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global high potency apis market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Application

• Oncology
• Hormonal Imbalance
• Glaucoma
• Others

By Type of Synthesis

• Synthetic
• Biotech
  • Type
  • Merchant
  • Captive

By Product Type

• Innovative High-Potency API
• Generic High-Potency API

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest Of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest Of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest Of LAMEA
• Key Market Players
  • AbbVie Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

• 1.1.Report description
• 1.2.Key market segments
• 1.3.Key benefits to the stakeholders
• 1.4.Research Methodology
  • 1.4.1.Secondary research
  • 1.4.2.Primary research
  • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

• 2.1.Key findings of the study
• 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

• 3.1.Market definition and scope
• 3.2.Key findings
  • 3.2.1.Top investment pockets
• 3.3.Porter's five forces analysis
• 3.4.Top player positioning
• 3.5.Market dynamics
  • 3.5.1.Drivers
  • 3.5.2.Restraints
  • 3.5.3.Opportunities
• 3.6.COVID-19 Impact Analysis on the market
• 3.7.Patent Landscape

CHAPTER 4: HIGH POTENCY APIS MARKET, BY PRODUCT TYPE

• 4.1 Overview
  • 4.1.1 Market size and forecast
• 4.2 Innovative High-Potency API
  • 4.2.1 Key market trends, growth factors and opportunities
  • 4.2.2 Market size and forecast, by region
  • 4.2.3 Market analysis by country
• 4.3 Generic High-Potency API
  • 4.3.1 Key market trends, growth factors and opportunities
  • 4.3.2 Market size and forecast, by region
  • 4.3.3 Market analysis by country

CHAPTER 5: HIGH POTENCY APIS MARKET, BY APPLICATION

• 5.1 Overview
  • 5.1.1 Market size and forecast
• 5.2 Oncology
  • 5.2.1 Key market trends, growth factors and opportunities
  • 5.2.2 Market size and forecast, by region
  • 5.2.3 Market analysis by country
• 5.3 Hormonal Imbalance
  • 5.3.1 Key market trends, growth factors and opportunities
  • 5.3.2 Market size and forecast, by region
  • 5.3.3 Market analysis by country
• 5.4 Glaucoma
  • 5.4.1 Key market trends, growth factors and opportunities
  • 5.4.2 Market size and forecast, by region
  • 5.4.3 Market analysis by country
• 5.5 Others
  • 5.5.1 Key market trends, growth factors and opportunities
  • 5.5.2 Market size and forecast, by region
  • 5.5.3 Market analysis by country

CHAPTER 6: HIGH POTENCY APIS MARKET, BY TYPE OF SYNTHESIS

• 6.1 Overview
  • 6.1.1 Market size and forecast
• 6.2 Synthetic
  • 6.2.1 Key market trends, growth factors and opportunities
  • 6.2.2 Market size and forecast, by region
  • 6.2.3 Market analysis by country
• 6.3 Biotech
  • 6.3.1 Key market trends, growth factors and opportunities
  • 6.3.2 Market size and forecast, by region
  • 6.3.3 Market analysis by country
  • 6.3.4 Biotech High Potency APIs Market by Type
    • 6.3.4.1 Merchant Market size and forecast, by region
    • 6.3.4.2 Captive Market size and forecast, by region

CHAPTER 7: HIGH POTENCY APIS MARKET, BY REGION

• 7.1 Overview
  • 7.1.1 Market size and forecast
• 7.2 North America
  • 7.2.1 Key trends and opportunities
  • 7.2.2 North America Market size and forecast, by Product Type
  • 7.2.3 North America Market size and forecast, by Application
  • 7.2.4 North America Market size and forecast, by Type of Synthesis
    • 7.2.4.1 North America Biotech High Potency APIs Market by Type
  • 7.2.5 North America Market size and forecast, by country
    • 7.2.5.1 U.S.
    • 7.2.5.1.1 Market size and forecast, by Product Type
    • 7.2.5.1.2 Market size and forecast, by Application
    • 7.2.5.1.3 Market size and forecast, by Type of Synthesis
    • 7.2.5.2 Canada
    • 7.2.5.2.1 Market size and forecast, by Product Type
    • 7.2.5.2.2 Market size and forecast, by Application
    • 7.2.5.2.3 Market size and forecast, by Type of Synthesis
    • 7.2.5.3 Mexico
    • 7.2.5.3.1 Market size and forecast, by Product Type
    • 7.2.5.3.2 Market size and forecast, by Application
    • 7.2.5.3.3 Market size and forecast, by Type of Synthesis
• 7.3 Europe
  • 7.3.1 Key trends and opportunities
  • 7.3.2 Europe Market size and forecast, by Product Type
  • 7.3.3 Europe Market size and forecast, by Application
  • 7.3.4 Europe Market size and forecast, by Type of Synthesis
    • 7.3.4.1 Europe Biotech High Potency APIs Market by Type
  • 7.3.5 Europe Market size and forecast, by country
    • 7.3.5.1 Germany
    • 7.3.5.1.1 Market size and forecast, by Product Type
    • 7.3.5.1.2 Market size and forecast, by Application
    • 7.3.5.1.3 Market size and forecast, by Type of Synthesis
    • 7.3.5.2 France
    • 7.3.5.2.1 Market size and forecast, by Product Type
    • 7.3.5.2.2 Market size and forecast, by Application
    • 7.3.5.2.3 Market size and forecast, by Type of Synthesis
    • 7.3.5.3 UK
    • 7.3.5.3.1 Market size and forecast, by Product Type
    • 7.3.5.3.2 Market size and forecast, by Application
    • 7.3.5.3.3 Market size and forecast, by Type of Synthesis
    • 7.3.5.4 Italy
    • 7.3.5.4.1 Market size and forecast, by Product Type
    • 7.3.5.4.2 Market size and forecast, by Application
    • 7.3.5.4.3 Market size and forecast, by Type of Synthesis
    • 7.3.5.5 Spain
    • 7.3.5.5.1 Market size and forecast, by Product Type
    • 7.3.5.5.2 Market size and forecast, by Application
    • 7.3.5.5.3 Market size and forecast, by Type of Synthesis
    • 7.3.5.6 Rest of Europe
    • 7.3.5.6.1 Market size and forecast, by Product Type
    • 7.3.5.6.2 Market size and forecast, by Application
    • 7.3.5.6.3 Market size and forecast, by Type of Synthesis
• 7.4 Asia-Pacific
  • 7.4.1 Key trends and opportunities
  • 7.4.2 Asia-Pacific Market size and forecast, by Product Type
  • 7.4.3 Asia-Pacific Market size and forecast, by Application
  • 7.4.4 Asia-Pacific Market size and forecast, by Type of Synthesis
    • 7.4.4.1 Asia-Pacific Biotech High Potency APIs Market by Type
  • 7.4.5 Asia-Pacific Market size and forecast, by country
    • 7.4.5.1 Japan
    • 7.4.5.1.1 Market size and forecast, by Product Type
    • 7.4.5.1.2 Market size and forecast, by Application
    • 7.4.5.1.3 Market size and forecast, by Type of Synthesis
    • 7.4.5.2 China
    • 7.4.5.2.1 Market size and forecast, by Product Type
    • 7.4.5.2.2 Market size and forecast, by Application
    • 7.4.5.2.3 Market size and forecast, by Type of Synthesis
    • 7.4.5.3 Australia
    • 7.4.5.3.1 Market size and forecast, by Product Type
    • 7.4.5.3.2 Market size and forecast, by Application
    • 7.4.5.3.3 Market size and forecast, by Type of Synthesis
    • 7.4.5.4 India
    • 7.4.5.4.1 Market size and forecast, by Product Type
    • 7.4.5.4.2 Market size and forecast, by Application
    • 7.4.5.4.3 Market size and forecast, by Type of Synthesis
    • 7.4.5.5 South Korea
    • 7.4.5.5.1 Market size and forecast, by Product Type
    • 7.4.5.5.2 Market size and forecast, by Application
    • 7.4.5.5.3 Market size and forecast, by Type of Synthesis
    • 7.4.5.6 Rest of Asia-Pacific
    • 7.4.5.6.1 Market size and forecast, by Product Type
    • 7.4.5.6.2 Market size and forecast, by Application
    • 7.4.5.6.3 Market size and forecast, by Type of Synthesis
• 7.5 LAMEA
  • 7.5.1 Key trends and opportunities
  • 7.5.2 LAMEA Market size and forecast, by Product Type
  • 7.5.3 LAMEA Market size and forecast, by Application
  • 7.5.4 LAMEA Market size and forecast, by Type of Synthesis
    • 7.5.4.1 LAMEA Biotech High Potency APIs Market by Type
  • 7.5.5 LAMEA Market size and forecast, by country
    • 7.5.5.1 Brazil
    • 7.5.5.1.1 Market size and forecast, by Product Type
    • 7.5.5.1.2 Market size and forecast, by Application
    • 7.5.5.1.3 Market size and forecast, by Type of Synthesis
    • 7.5.5.2 Saudi Arabia
    • 7.5.5.2.1 Market size and forecast, by Product Type
    • 7.5.5.2.2 Market size and forecast, by Application
    • 7.5.5.2.3 Market size and forecast, by Type of Synthesis
    • 7.5.5.3 South Africa
    • 7.5.5.3.1 Market size and forecast, by Product Type
    • 7.5.5.3.2 Market size and forecast, by Application
    • 7.5.5.3.3 Market size and forecast, by Type of Synthesis
    • 7.5.5.4 Rest of LAMEA
    • 7.5.5.4.1 Market size and forecast, by Product Type
    • 7.5.5.4.2 Market size and forecast, by Application
    • 7.5.5.4.3 Market size and forecast, by Type of Synthesis

CHAPTER 8: COMPANY LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

• 9.1 AbbVie Inc.
  • 9.1.1 Company overview
  • 9.1.2 Company snapshot
  • 9.1.3 Operating business segments
  • 9.1.4 Product portfolio
  • 9.1.5 Business performance
  • 9.1.6 Key strategic moves and developments
• 9.2 Bayer AG
  • 9.2.1 Company overview
  • 9.2.2 Company snapshot
  • 9.2.3 Operating business segments
  • 9.2.4 Product portfolio
  • 9.2.5 Business performance
  • 9.2.6 Key strategic moves and developments
• 9.3 Boehringer Ingelheim International GmbH
  • 9.3.1 Company overview
  • 9.3.2 Company snapshot
  • 9.3.3 Operating business segments
  • 9.3.4 Product portfolio
  • 9.3.5 Business performance
  • 9.3.6 Key strategic moves and developments
• 9.4 Bristol-Myers Squibb Company
  • 9.4.1 Company overview
  • 9.4.2 Company snapshot
  • 9.4.3 Operating business segments
  • 9.4.4 Product portfolio
  • 9.4.5 Business performance
  • 9.4.6 Key strategic moves and developments
• 9.5 Eli Lilly and Company
  • 9.5.1 Company overview
  • 9.5.2 Company snapshot
  • 9.5.3 Operating business segments
  • 9.5.4 Product portfolio
  • 9.5.5 Business performance
  • 9.5.6 Key strategic moves and developments
• 9.6 F. Hoffmann-La Roche
  • 9.6.1 Company overview
  • 9.6.2 Company snapshot
  • 9.6.3 Operating business segments
  • 9.6.4 Product portfolio
  • 9.6.5 Business performance
  • 9.6.6 Key strategic moves and developments
• 9.7 Novartis International AG
  • 9.7.1 Company overview
  • 9.7.2 Company snapshot
  • 9.7.3 Operating business segments
  • 9.7.4 Product portfolio
  • 9.7.5 Business performance
  • 9.7.6 Key strategic moves and developments
• 9.8 Pfizer, Inc.
  • 9.8.1 Company overview
  • 9.8.2 Company snapshot
  • 9.8.3 Operating business segments
  • 9.8.4 Product portfolio
  • 9.8.5 Business performance
  • 9.8.6 Key strategic moves and developments
• 9.9 Sanofi
  • 9.9.1 Company overview
  • 9.9.2 Company snapshot
  • 9.9.3 Operating business segments
  • 9.9.4 Product portfolio
  • 9.9.5 Business performance
  • 9.9.6 Key strategic moves and developments
• 9.10 Teva Pharmaceutical Industries Ltd.
  • 9.10.1 Company overview
  • 9.10.2 Company snapshot
  • 9.10.3 Operating business segments
  • 9.10.4 Product portfolio
  • 9.10.5 Business performance
  • 9.10.6 Key strategic moves and developments